China News Service, November 1 reported that on October 31, the US White House Spokesperson Psaki confirmed that he was infected with the new crown virus.
Psaki said that the last time she met with US President Biden was on October 26, and did not visit Europe with him.
On the other hand, the U.S. Food and Drug Administration (FDA) informed Modena that more time is needed to complete the evaluation of the company’s vaccine for adolescents aged 12 to 17.
Data map: White House Spokesperson Jane Psaki.
Photo by Zhang Weiran posted by China News Service
[White House Spokesperson Psaki Infects New Crown]
Biden previously went to Rome to attend the Group of 20 (G20) Leaders Summit, and will travel to Glasgow on November 1 to attend the 26th Conference of the Parties to the UN Climate Change Framework Convention (COP26).
Psaki, 42, originally planned to travel with Biden, but cancelled the trip after learning that her family was infected.
Psaki issued a statement saying: "Since then, I have been quarantined from the 27th to the 30th and performed a PCR test. The result was negative, but today (October 31) I was diagnosed."
Psaki said that the last time she met with Biden was on October 26, when the two met at the White House and kept a distance of 6 feet (about 180 cm) and wore masks.
She said that she currently has only mild symptoms of the infection.
This time it was the White House Deputy Spokesperson Karine Jean-Pierre who accompanied Biden to visit. Psaki said that after the 10-day quarantine period ends and a quick test test negative, she will return to work.
The White House staff and entourage who accompanied Biden to Europe were screened every day before leaving the White House and were fully vaccinated. Due to close contact with people and frequent business trips for their duties, many officials have been vaccinated with boosters.
Data map: On July 30, local time, a New York State citizen wears a mask while shopping in a supermarket on Long Island.
Photo by China News Agency reporter Liao Pan
[The progress of the review of the modena vaccination for adolescents has been delayed]
Modena said on October 31 that the U.S. Food and Drug Administration (FDA) will need more time to complete the company's evaluation of the new crown vaccine for adolescents aged 12 to 17.
The company said in a statement that the FDA notified the company that this review may not be completed before January 2022, which may set back the progress of the emergency use authorization (EUA) for this age group.
Modena said the company was told that the FDA needed additional time to evaluate a recent international analysis of the risk of post-vaccination myocarditis, a rare side effect that mainly affects young men.
Modena said it is reviewing a new external analysis of the increased risk of myocarditis in people under the age of 18.
In June of this year, Modena applied to the United States for an emergency use authorization of the vaccine for people aged 12 to 17.
Currently, only Pfizer vaccines are available for Americans this year.
Modena also said that while the FDA completes its review of applications for 12 to 17 years of age, it will postpone the EUA application for a half-dose pediatric vaccine for children aged 6-11.